Literature DB >> 3266358

Presence of interferon and anti-interferon in patients with systemic lupus erythematosus.

P von Wussow1, D Jakschies, K Hartung, H Deicher.   

Abstract

Sera from 61 patients with systemic lupus erythematosus (SLE) were serially screened over a period of at least 2 years for IFN and anti-IFN antibodies. IFN concentrations were measured both with a cytopathic effect assay and a more sensitive radioimmunoassay. Of the patients 15% (9/61) had IFN in their serum at one or more occasions as measured in the bioassay (greater than or equal to 6 IU/ml); employing a RIA (greater than or equal to 1 IU/ml) 28% (17/61) of the patients studied were positive for IFN-alpha. Fifteen patients had a measurable interferonemia over 2-16 months; only two patients had detectable IFN in their serum at only one occasion. In five patients, hourly and daily variations of the IFN titer as measured by RIA were found to amount to less than 80%. The IFN activity found in these sera was characterized as IFN-alpha by means of acid stability, cross-reactivity on heterologous cells, trypsin sensitivity, and neutralization by homologous and heterologous antisera. IFN antibodies were quantified with a neutralization bioassay, an ELISA, and a radioimmunoassay. Of the 61 patients 5% (3) possessed high titers of anti-IFN antibodies which persisted over 2 years. The IFN-alpha antibody positive patients had an inactive form of the disease over years without visceral involvement but decreased serum complement levels (C4, C3, CH50) and repeated episodes of Quincke-like edema.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3266358     DOI: 10.1007/bf00269199

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  19 in total

1.  Inhibition of virus multiplication by foreign nucleic acid.

Authors:  Z ROTEM; R A COX; A ISAACS
Journal:  Nature       Date:  1963-02-09       Impact factor: 49.962

2.  Interferon treatment of NZB mice: accelerated progression of autoimmune disease.

Authors:  H Heremans; A Billiau; A Colombatti; J Hilgers; P de Somer
Journal:  Infect Immun       Date:  1978-09       Impact factor: 3.441

3.  AN INHIBITOR OF VIRAL ACTIVITY APPEARING IN INFECTED CELL CULTURES.

Authors:  M Ho; J F Enders
Journal:  Proc Natl Acad Sci U S A       Date:  1959-03       Impact factor: 11.205

4.  Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon alfa-2a by intramuscular injection.

Authors:  L M Itri; M Campion; R A Dennin; A V Palleroni; J U Gutterman; J E Groopman; P W Trown
Journal:  Cancer       Date:  1987-02-01       Impact factor: 6.860

5.  Two distinct families of human and bovine interferon-alpha genes are coordinately expressed and encode functional polypeptides.

Authors:  D J Capon; H M Shepard; D V Goeddel
Journal:  Mol Cell Biol       Date:  1985-04       Impact factor: 4.272

6.  Interferon assay as a diagnostic test.

Authors:  R P Parry; J V Parry
Journal:  Lancet       Date:  1981-02-28       Impact factor: 79.321

7.  Evidence that types I and II interferons have different receptors.

Authors:  A A Branca; C Baglioni
Journal:  Nature       Date:  1981-12-24       Impact factor: 49.962

8.  Adverse effects of interferon treatment on the life span of NZB mice.

Authors:  D Sergiescu; I Cerutti; E Efthymiou; A Kahan; C Chany
Journal:  Biomedicine       Date:  1979-04

9.  Systemic lupus erythematosus: presence in human serum of an unusual acid-labile leukocyte interferon.

Authors:  O T Preble; R J Black; R M Friedman; J H Klippel; J Vilcek
Journal:  Science       Date:  1982-04-23       Impact factor: 47.728

10.  Persistent expression of Ia antigen and viral genome in visna-maedi virus-induced inflammatory cells. Possible role of lentivirus-induced interferon.

Authors:  P G Kennedy; O Narayan; Z Ghotbi; J Hopkins; H E Gendelman; J E Clements
Journal:  J Exp Med       Date:  1985-12-01       Impact factor: 14.307

View more
  16 in total

1.  Intracellular staining of Mx proteins in cells from peripheral blood, bone marrow and skin.

Authors:  A N al-Masri; T Werfel; D Jakschies; P von Wussow
Journal:  Mol Pathol       Date:  1997-02

2.  Plasmacytoid dendritic cells (natural interferon- alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions.

Authors:  L Farkas; K Beiske; F Lund-Johansen; P Brandtzaeg; F L Jahnsen
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

3.  Patients with systemic lupus erythematosus (SLE) have a circulating inducer of interferon-alpha (IFN-alpha) production acting on leucocytes resembling immature dendritic cells.

Authors:  H Vallin; S Blomberg; G V Alm; B Cederblad; L Rönnblom
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

Review 4.  The cytokine network in the pathogenesis of systemic lupus erythematosus and possible therapeutic implications.

Authors:  D A Horwitz; C O Jacob
Journal:  Springer Semin Immunopathol       Date:  1994

5.  Type I interferon correlates with serological and clinical manifestations of SLE.

Authors:  M C Dall'era; P M Cardarelli; B T Preston; A Witte; J C Davis
Journal:  Ann Rheum Dis       Date:  2005-04-20       Impact factor: 19.103

6.  Characterization of Type-I IFN subtype autoantibodies and activity in SLE serum and urine.

Authors:  Bethany D Harris; Srilalitha Kuruganti; Ashlesha Deshpande; Paul A Goepfert; W Winn Chatham; Mark R Walter
Journal:  Lupus       Date:  2020-07-01       Impact factor: 2.911

7.  Association of endogenous anti-interferon-α autoantibodies with decreased interferon-pathway and disease activity in patients with systemic lupus erythematosus.

Authors:  Alyssa M Morimoto; Donna Thibault Flesher; Jihong Yang; Kristen Wolslegel; Xiangdan Wang; Ann Brady; Alexander R Abbas; Valerie Quarmby; Eric Wakshull; Bruce Richardson; Michael J Townsend; Timothy W Behrens
Journal:  Arthritis Rheum       Date:  2011-08

8.  No synergistic activity of epirubicin and interferon-alpha 2b in the treatment of hepatocellular carcinoma.

Authors:  C Bokemeyer; B Kynast; A Harstrick; E Laage; E Schmoll; P von Wussow; H J Schmoll
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

9.  High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus.

Authors:  T B Niewold; J Hua; T J A Lehman; J B Harley; M K Crow
Journal:  Genes Immun       Date:  2007-06-21       Impact factor: 2.676

Review 10.  Cytokine-producing dendritic cells in the pathogenesis of inflammatory skin diseases.

Authors:  Leanne M Johnson-Huang; N Scott McNutt; James G Krueger; Michelle A Lowes
Journal:  J Clin Immunol       Date:  2009-02-28       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.